When India was still negotiating the terms of independence, the colonial administration enacted the Pharmacy Act of 1948 — a statute designed to create a register of pharmacists and call it a day. Seventy-eight years later, that same law governs the licensing and education of pharmacists across a country that has become the world's third-largest pharmaceutical producer by volume and the dominant global supplier of generic medicines. The mismatch between ambition and architecture has been widening for decades. The government now proposes to close it.
The National Pharmacy Commission Bill, 2026, tabled by the Union Health Ministry, would abolish the Pharmacy Council of India and replace it with a new central commission seated in New Delhi. The commission will comprise a chairperson, 15 ex officio members drawn from health ministries and related agencies, and 13 part-time members representing states across six zones. Commission leaders serve a single term of up to four years with no reappointment option and must vacate office at age 70 — a term-limit architecture that mirrors the National Medical Commission's design and is explicitly intended to prevent the institutional capture that plagued the bodies it replaced.
Four Boards, One Standard
The bill's operating logic rests on disaggregation. Rather than a single monolithic council — which is exactly what the Pharmacy Council of India became — four independent boards will operate under the commission, each with a distinct mandate. The Pharmacy Education Board for the Modern System of Medicine and its counterpart for the Indian System of Medicine and Homoeopathy will design curricula for their respective streams. A Pharmacy Assessment and Rating Board will inspect colleges and approve new institutions. A Pharmacy Ethics and Registration Board will handle professional conduct and maintain a central database of practitioners.
The enforcement teeth sit with the Assessment and Rating Board. If an institution fails minimum standards, the board can halt admissions, cut seat capacities, or impose fines ranging from one-tenth to five times the total fees charged for a student batch. That is a graduated penalty structure — not a binary revoke-or-ignore choice — and it matters. The existing framework's weakness was that regulators had too few tools between full approval and closure. Most chose to look away.
A temporary Board of Governors will manage operations for up to a year while the permanent commission assembles, preserving administrative continuity across the transition. This bridging mechanism, absent from some earlier regulatory overhauls, reflects institutional maturity in the bill's drafting.
The Exit Exam: Where the Real Stakes Sit
The bill's most consequential provision is the National Exit Test (Pharmacy) — a mandatory examination that every pharmacy graduate must clear before receiving a practice licence. The test will also serve as the gateway for postgraduate admissions. The logic mirrors that of the NEET examination for medical students: sever the automatic link between degree-granting and practice-licensing.
That link is the single most corrosive feature of the current system. An institution could offer a pharmacy degree of almost any quality, and its graduates would walk into practice with full legal standing. The exit exam breaks that chain. A degree from a substandard college in a tier-three town no longer automatically qualifies someone to dispense medicines to patients; they must demonstrate competency against a national benchmark. For a country with 8,000 pharmacy colleges and over 500,000 students in the system, that is a structural reset.
The Export Credibility Problem
India's pharmaceutical industry operates on a paradox. The country supplies generic drugs to health systems across North America, Europe, and Africa at prices no other producer can match. But the domestic quality assurance framework for the professionals who dispense medicines has remained frozen in a colonial design. US FDA import alerts and scrutiny from the UK's MHRA have targeted specific Indian manufacturing facilities — not primarily because of chemistry failures, but because of systemic quality culture gaps. Domestic dispensing standards and the education quality of pharmacists feeding into the supply chain are part of that culture.
A central registry of pharmacists — one of the bill's provisions — directly addresses what regulators in export markets have long identified as an opacity problem: the absence of a reliable, nationally consistent record of who is authorised to practise. The new architecture also explicitly allows for global recognition of Indian pharmacy degrees, a provision that matters commercially. Indian-trained pharmacists work across the Gulf, East Africa, and Southeast Asia in significant numbers. Mutual recognition agreements with those markets require the Indian degree to carry verifiable quality assurance — which the existing framework cannot credibly provide.
The Indian Pharmaceutical Alliance, representing large domestic manufacturers, has argued that upgraded dispensing standards protect the brand integrity of Indian generics in export markets. A dispensing scandal in a key export market, traced back to a poorly trained Indian pharmacist, damages the entire sector's reputation. The bill's quality architecture answers that concern directly.
The Federalism Tension
The reform is not friction-free. The Pharmacy Council of India has raised concerns about loss of institutional autonomy. Former PCI President B. Suresh has publicly questioned whether centralisation will reduce responsiveness to regional needs. State governments run large public health pharmacy networks, and state-level regulatory familiarity with local conditions has genuine value. A central commission that sets curriculum from New Delhi does not automatically understand the dispensing requirements of a primary health centre in rural Odisha or a tribal district in Chhattisgarh.
The parallel with the National Medical Commission Act, 2020 — which replaced the Medical Council of India under near-identical political and institutional logic — is instructive. The NMC faced similar federalism concerns at inception, and its early years involved real friction between the central board and state medical universities over curriculum autonomy. The pharmacy bill's zone-based representation of states in the commission structure is a partial answer to that concern; whether it is sufficient will depend on implementation. A phased rollout that gives states co-governance provisions over public health pharmacy networks — while holding the exit exam standard firm nationally — would reduce political resistance without diluting the central quality floor.
What the Bill Gets Right — and What It Leaves Open
The bill's inclusion of traditional medicine and homoeopathy within a unified regulatory framework — through a dedicated education board rather than a parallel silo — is a structural choice worth noting. India's pharmacy landscape is genuinely pluralistic; a law that regulates only modern pharmacy while leaving AYUSH dispensing in a separate, lighter-touch framework creates quality arbitrage. The integrated approach is the correct architecture.
What the bill does not yet answer is the design of the exit exam itself. An exit examination calibrated only to dispensing knowledge — drug-drug interactions, dosage arithmetic, labelling rules — will produce better pharmacists than the current system, but it will not produce the clinical pharmacists that India's health services export ambitions require. Clinical pharmacy, where pharmacists actively participate in patient care and medication management, remains a nascent discipline domestically. If the exit exam incorporates clinical competencies aligned with WHO Good Pharmacy Practice guidelines, it opens the door to the kind of international mutual recognition that could transform Indian-trained pharmacists from lower-cost substitutes into credentialed professionals in high-income health systems. That design choice — exam content, not exam existence — will ultimately determine how much of the bill's potential the sector actually captures.
The Pharmacy Act of 1948 was never designed for a country that would one day supply the world's generic drug needs. Its repeal is overdue. The National Pharmacy Commission Bill, 2026 offers the architecture to replace it — but architecture is not outcome. The quality of the exit exam, the speed of the accreditation drive for underperforming colleges, and the willingness to grant states genuine co-governance over public networks will determine whether this reform hardens into a durable quality system or softens, over time, into another council with a different name.
